OPKO Surpasses 50% Enrollment in Second Phase 3 Trial of Rayaldya

OPKO Health, Inc. , has surpassed 50% enrollment in the second phase 3 trial of Rayaldy a to treat patients with secondary hyperparathyroidism , stage 3 or 4 chronic kidney disease and vitamin D insufficiency.

http://www.businesswire.com/news/topix/20130815005911/en